Psühhootilise häirega patsientidele mõeldud metaboolse sündroomi riski prognoosimudeli valideerimine Eesti geenivaramu andmetel
Laen...
Kuupäev
Autorid
Ajakirja pealkiri
Ajakirja ISSN
Köite pealkiri
Kirjastaja
Tartu Ülikool
Abstrakt
Käesoleva töö eesmärk oli testida Tartu Ülikooli Eesti geenivaramu andmete peal Ühendkuningriigis välja töötatud mudelit, millega on võimalik prognoosida psühhootilise häire diagnoosiga indiviididel metaboolse sündroomi kujunemise riski järgmise viie aasta jooksul. Samuti oli üheks eesmärgiks hinnata, kas psühhootilise diagnoosiga indiviidide jaoks koostatud metaboolse sündroomi riski prognoosiv mudel on sobiv kasutamiseks ka üldpopulatsioonis ehk kontrollrühma jaoks. Esmalt selgitati, mida mõeldakse psühhootiliste häirete all, mis on metaboolne sündroom ja mis mudelid on välja töötatud. Seejärel selgitati, milliste kriteeriumite alusel Eesti geenivaramu andmetel psühhootilise diagnoosiga indiviidide ja kontrollide valimid koostati. Kirjeldati ka metoodikat: mida tähendab mudeli sobivuse hindamine ning milleks kasutatakse
Hosmer-Lemeshow testi. Seejärel anti ülevaade andmestikest koos kirjeldava analüüsiga ning selgitati, miks käesolevas töös testitakse ainult Ühendkuningriigis välja töötatud osalist mudelit. Viimaks analüüsitakse andmeid, esitatakse analüüsitulemused ja järeldused.
The aim of this study was to test a model that predicts the risk of metabolic syndrome within the next five years among individuals with a psychotic disorder. The model was developed in the UK specifically for individuals with a psychotic disorder and in this thesis tested using data from the Estonian Biobank. Additionally, we set out to investigate whether the proposed model predicts the risk of developing metabolic syndrome also in the general population (referred here as the control group). First, an overview of psychotic disorders and the metabolic syndrome was outlined, and the UK-developed prediction model was introduced. Next, the criteria used to define the sample of individuals with psychotic disorders and the control set in the Estonian Biobank were given, and the methodological background was presented, including the concept of the goodness of fit for the model and the purpose of the Hosmer-Lemeshow test. Finally, an overview of the datasets with descriptive analyses were outlined together with the rationale for testing only the partial UK-developed model. Lastly, the analysis process and results with conclusions were presented.
The aim of this study was to test a model that predicts the risk of metabolic syndrome within the next five years among individuals with a psychotic disorder. The model was developed in the UK specifically for individuals with a psychotic disorder and in this thesis tested using data from the Estonian Biobank. Additionally, we set out to investigate whether the proposed model predicts the risk of developing metabolic syndrome also in the general population (referred here as the control group). First, an overview of psychotic disorders and the metabolic syndrome was outlined, and the UK-developed prediction model was introduced. Next, the criteria used to define the sample of individuals with psychotic disorders and the control set in the Estonian Biobank were given, and the methodological background was presented, including the concept of the goodness of fit for the model and the purpose of the Hosmer-Lemeshow test. Finally, an overview of the datasets with descriptive analyses were outlined together with the rationale for testing only the partial UK-developed model. Lastly, the analysis process and results with conclusions were presented.
Kirjeldus
Märksõnad
geenivaramu, metaboolne sündroom, psühhootilised häired, Hosmer-Lemeshow test, biobank, metabolic syndrome, psychotic disorders, Hosmer-Lemeshow test